Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H1FL
|
|||
| Former ID |
DIB005906
|
|||
| Drug Name |
PF-514273
|
|||
| Synonyms |
PF 514273; 2-(2-CHLOROPHENYL)-3-(4-CHLOROPHENYL)-7-(2,2-DIFLUOROPROPYL)-6,7-DIHYDRO-2H-PYRAZOLO[3,4-F][1,4]OXAZEPIN-8(5H)-ONE; FJMQJSUOOGOWBD-UHFFFAOYSA-N; SCHEMBL1315434; CHEMBL484929; BDBM29075; DTXSID80462142; MolPort-023-276-895; ZINC40939374; AKOS024457743; API0006251; NCGC00370822-01; PF-0514273; FT-0673651; PF-514273, >
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Discontinued in Phase 1 | [1] | |
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H17Cl2F2N3O2
|
|||
| Canonical SMILES |
CC(CN1CCOC2=C(N(N=C2C1=O)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)(F)F
|
|||
| InChI |
1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3
|
|||
| InChIKey |
FJMQJSUOOGOWBD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 851728-60-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Modulator | [2] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025584) | |||
| REF 2 | Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.